Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Return on Sales (2021 - 2025)

Tarsus Pharmaceuticals has reported Return on Sales over the past 5 years, most recently at 0.04% for Q4 2025.

  • Quarterly results put Return on Sales at 0.04% for Q4 2025, up 31.0% from a year ago — trailing twelve months through Dec 2025 was 0.14% (up 48.0% YoY), and the annual figure for FY2025 was 0.15%, up 48.0%.
  • Return on Sales for Q4 2025 was 0.04% at Tarsus Pharmaceuticals, up from 0.11% in the prior quarter.
  • Over the last five years, Return on Sales for TARS hit a ceiling of 0.33% in Q2 2021 and a floor of 42.87% in Q4 2021.
  • Median Return on Sales over the past 5 years was 1.03% (2024), compared with a mean of 7.06%.
  • Peak annual rise in Return on Sales hit 4151bps in 2022, while the deepest fall reached -3712bps in 2022.
  • Tarsus Pharmaceuticals' Return on Sales stood at 42.87% in 2021, then skyrocketed by 97bps to 1.36% in 2022, then crashed by -138bps to 3.25% in 2023, then skyrocketed by 89bps to 0.35% in 2024, then skyrocketed by 88bps to 0.04% in 2025.
  • The last three reported values for Return on Sales were 0.04% (Q4 2025), 0.11% (Q3 2025), and 0.2% (Q2 2025) per Business Quant data.